Singapore markets closed

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.1900-0.0400 (-3.25%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 88.93M
Enterprise value 54.51M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.52
Price/book (mrq)N/A
Enterprise value/revenue 6.45
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.36
52-week change 3-10.53%
S&P500 52-week change 323.76%
52-week high 32.1200
52-week low 30.6500
50-day moving average 31.2949
200-day moving average 31.1847

Share statistics

Avg vol (3-month) 3245.46k
Avg vol (10-day) 3137.94k
Shares outstanding 574.73M
Implied shares outstanding 674.73M
Float 865.2M
% held by insiders 17.47%
% held by institutions 131.58%
Shares short (15 May 2024) 4343.32k
Short ratio (15 May 2024) 41.79
Short % of float (15 May 2024) 40.49%
Short % of shares outstanding (15 May 2024) 40.46%
Shares short (prior month 15 Apr 2024) 4265.28k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-3,569.13%

Management effectiveness

Return on assets (ttm)-37.49%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)8.45M
Revenue per share (ttm)0.13
Quarterly revenue growth (yoy)5,650.00%
Gross profit (ttm)N/A
EBITDA -25.37M
Net income avi to common (ttm)-34.97M
Diluted EPS (ttm)-0.5500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.35M
Total cash per share (mrq)0.47
Total debt (mrq)45.33M
Total debt/equity (mrq)N/A
Current ratio (mrq)6.07
Book value per share (mrq)-0.29

Cash flow statement

Operating cash flow (ttm)-18.77M
Levered free cash flow (ttm)-17.98M